EMA Reviewing Two Centralised Switch Applications
Executive Summary
Teva's Ratiopharm and Italy's Recordati have submitted applications to switch drugs from prescription-to-OTC status through EMA's centralised procedure. Given only four products have been switched centrally to date, a double reclassification would be unprecedented.
You may also be interested in...
Fortacin: EMA Recommends Fifth EU-Wide Rx-to-OTC Switch
Premature ejaculation treatment Fortacin is set to become only the fifth drug to achieve an Rx-to-OTC switch through European Medicines Agency's centralized procedure, expanding the burgeoning OTC men's sexual health category.
EMA Approves EU-Wide Rx-to-OTC Switch Of Fortacin
Premature ejaculation treatment Fortacin is set to become only the fifth drug to achieve an Rx-to-OTC switch through EMA's centralized procedure, expanding the burgeoning OTC men's sexual health category.
EU-Wide Switch Of Premature Ejaculation Drug A Real Prospect
EMA's CHMP is considering an EU-wide switch of premature ejaculation drug Fortacin, with applicant Recordati eyeing a January 2021 launch for the OTC treatment.